Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer-Reference-Cited by-同舟云学术

Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer

Published:2016-11-12 Issue:5 Volume:119 Page:667-675
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Gilbert Duncan C.¹,Duong Trinh¹,Kynaston Howard G.²,Alhasso Abdulla A.³,Cafferty Fay H.¹,Rosen Stuart D.⁴,Kanaga-Sundaram Subramanian⁵,Dixit Sanjay⁶,Laniado Marc⁷,Madaan Sanjeev⁸,Collins Gerald⁹,Pope Alvan¹⁰,Welland Andrew¹,Nankivell Matthew¹,Wassersug Richard¹¹,Parmar Mahesh K. B.¹,Langley Ruth E.¹,Abel Paul D.¹²¹³

Affiliation:

1. Medical Research Council Clinical Trials Unit at University College London; London UK

2. Cardiff School of Medicine; Cardiff University; Cardiff UK

3. The Beatson West of Scotland Cancer Centre; Glasgow UK

4. National Heart and Lung Institute; Imperial College London; London UK

5. Mid-Yorkshire Hospitals NHS Trust; Pinderfields General Hospital; Wakefield UK

6. Scunthorpe General Hospital; North Lincolnshire and Goole NHS Trust; Scunthorpe UK

7. Frimley Health NHS Foundation Trust; Wexham Park Hospital; Slough UK

8. Dartford and Gravesham NHS Trust; Darent Valley Hospital; Dartford UK

9. Stockport NHS Foundation Trust; Stepping Hill Hospital; Stockport UK

10. The Hillingdon Hospitals NHS Foundation Trust; London UK

11. University of British Columbia; Vancouver BC Canada

12. Imperial College Healthcare NHS Trust; London UK

13. Imperial College London; London UK

Funder

Cancer Research UK

University College London

Imperial College London

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13687/fullpdf

Reference52 articles.

1. National Cancer Institute SEER Stat Fact Sheets: Prostate Cancer http://seer.cancer.gov/statfacts/html/prost.html

2. Cancer Research UK Prostate cancer statistics http://wwwcancerresearchukorg/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer

3. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial;D'Amico;JAMA,2008

4. Radiotherapy and short-term androgen deprivation for localized prostate cancer;Jones;N Engl J Med,2011

5. Duration of androgen suppression in the treatment of prostate cancer;Bolla;N Engl J Med,2009

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579–87;European Urology;2024-06

2. Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management;American Society of Clinical Oncology Educational Book;2024-06

3. The Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males;Journal of the Endocrine Society;2024-05-23

4. Low dose of propyl-pyrazole-triol, an agonist of estrogen receptor alpha, administration stimulates the Coolidge effect in fadrozole-treated male rats;Hormones and Behavior;2024-05

5. Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol;BJU International;2024-04-08